To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg

Sandoz

Status and phase: Completed; Phase 1

Conditions: Hypertension; Angina

Treatments: Drug: Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.); Drug: Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00946725

11627

Details and patient eligibility

About

To demonstrate the relative bioavailability of atenolol tablets, 100 mg.

Enrollment: 28 patients

Sex: Male

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

• Positive test results for HIV or hepatitis B or C.
• Treatment for drug or alcohol dependence.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

28 participants in 2 patient groups

1

Experimental group

Description:

Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

Treatment:

Drug: Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

2

Active Comparator group

Description:

Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Treatment:

Drug: Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)